香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代碼：00719） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 山 東 新 華 製 藥 股 份 有 限 公 司 （ 「 本 公 司 」 ） 將 於 2025 年 11 月 28 日 在 巨 潮 資 訊 網 （http://www.cninfo.com.cn）刊登的本公司《關於獲得醋酸潑尼松龍化學原料藥上市申請批准通知 書的公告》,茲載列有關文檔之中文版，以供參閱。 山東新華製藥股份有限公司 承董事會命 关于获得醋酸泼尼松龙化学原料药上市申请批准通知书的公告 賀同慶 董事長 中國 淄博 2025年11月27日 於本公告日期，本公司董事會之成員如下： | 執行董事： | | 獨立非執行董事： | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代碼：00719） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 山 東 新 華 製 藥 股 份 有 限 公 司 （ 「 本 公 司 」 ） 將 於 2025 年 11 月 28 日 在 巨 潮 資 訊 網 （http://www.cninfo.com.cn）刊登的本公司《關於鹽酸腎上腺素註射液通過仿製藥一致性評價的公 告》,茲載列有關文檔之中文版，以供參閱。 承董事會命 山東新華製藥股份有限公司 賀同慶 董事長 中國 淄博 2025年11月27日 於本公告日期，本公司董事會之成員如下： | 執行董事： | | 獨立非執行董事： | | --- | --- | --- | | 賀同慶先生（董事長） | ...

Core Viewpoint - The pet economy sector experienced a slight increase of 0.14% on November 26, with Renmin Tongtai leading the gains, while the overall market showed mixed results with the Shanghai Composite Index down by 0.15% and the Shenzhen Component Index up by 1.02% [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3864.18, down 0.15% [1] - The Shenzhen Component Index closed at 12907.83, up 1.02% [1] - The pet economy sector stocks showed varied performance, with Renmin Tongtai rising by 10.02% to a closing price of 13.18 [1] Group 2: Individual Stock Performance - Renmin Tongtai (600829) led the sector with a closing price of 13.18 and a trading volume of 538,900 shares, resulting in a transaction value of 672 million [1] - Aoni Electronics (301189) increased by 6.34% to 40.09, with a transaction value of 332 million [1] - Xinhua Pharmaceutical (000756) rose by 5.77% to 18.15, with a transaction value of 159.5 million [1] Group 3: Capital Flow - The pet economy sector saw a net outflow of 27.86 million from institutional investors and 74.23 million from retail investors, while retail investors had a net inflow of 102 million [2][3] - Renmin Tongtai experienced a net inflow of 115 million from institutional investors, despite a net outflow of 51.93 million from retail investors [3] - Xinhua Pharmaceutical had a net inflow of 68.19 million from institutional investors, with a net outflow of 21.72 million from retail investors [3]

Market Performance - The Shandong state-owned enterprise reform sector rose by 0.45% compared to the previous trading day, with Xinhua Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Highlights - Xinhua Pharmaceutical (000756) closed at 18.15, up 5.77% with a trading volume of 877,900 shares and a transaction value of 1.595 billion [1] - Inspur Information (000977) closed at 63.56, up 5.74% with a trading volume of 995,400 shares and a transaction value of 6.266 billion [1] - Other notable stocks include Jiri Co. (002083) up 3.50%, Shantui Co. (000680) up 3.02%, and Haizhu Co. (301262) up 3.01% [1] Capital Flow - The Shandong state-owned enterprise reform sector saw a net inflow of 885 million in main funds, while retail investors experienced a net outflow of 449 million [2] - The main funds showed significant inflows into stocks like Inspur Information and Xinhua Pharmaceutical, while retail investors withdrew from several stocks [3] Individual Stock Capital Flow - Inspur Information had a main fund net inflow of 11.37 billion, while retail investors saw a net outflow of 6.40 billion [3] - Xinhua Pharmaceutical experienced a main fund net inflow of 68.2 million, with retail investors withdrawing 46.5 million [3] - Other stocks like Shandong Steel (600022) and Qingdao Food (001219) also showed varied capital flows, indicating differing investor sentiments [3]

Core Viewpoint - The chemical pharmaceutical sector experienced a rise of 1.66% on November 26, with Frontier Biotech leading the gains, while the overall Shanghai Composite Index fell by 0.15% [1]. Group 1: Stock Performance - Frontier Biotech (688221) closed at 20.20, up 12.85% with a trading volume of 455,500 shares and a transaction value of 916 million yuan [1]. - Yuyuan Pharmaceutical (688658) closed at 26.88, up 12.00% with a trading volume of 218,600 shares and a transaction value of 577 million yuan [1]. - Fuyuan Pharmaceutical (6801089) closed at 24.53, up 10.00% with a trading volume of 113,800 shares and a transaction value of 274 million yuan [1]. - Other notable performers include Guangji Pharmaceutical (000952) with a 9.99% increase and Beida Pharmaceutical (000788) with a 9.94% increase [1]. Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 43.08 million yuan from institutional investors, while retail investors contributed a net inflow of 23.8 million yuan [2]. - The sector experienced a net outflow of 281 million yuan from speculative funds [2]. - Key stocks with significant fund flows include Heng Rui Pharmaceutical (600276) with a net inflow of 231 million yuan from institutional investors [3]. Group 3: Individual Stock Fund Flow - New China Pharmaceutical (000756) had a net inflow of 68.2 million yuan from institutional investors, while experiencing a net outflow of 21.7 million yuan from speculative funds [3]. - Fuyuan Pharmaceutical (601089) saw a net inflow of 67.6 million yuan from institutional investors, with a net outflow of 39.4 million yuan from speculative funds [3]. - Other stocks like Beibete (688759) and Yuyuan Pharmaceutical (688658) also showed varying levels of net inflows and outflows from different investor categories [3].

Group 1 - Runjian Co., Ltd. is planning to issue H-shares and list on the Hong Kong Stock Exchange [1] - Zhongfu Shenying's shareholder plans to reduce its stake by no more than 1% [2] - Chenxi Aviation's controlling shareholder intends to reduce its stake by up to 3% [2] Group 2 - Zhiguang Electric's subsidiary signed a sales contract worth 152 million yuan [3] - Sanrenxing's controlling shareholder and actual controller plan to transfer up to 8% of the company's shares [4] - Guosheng Technology intends to acquire 100% equity of Fuyue Technology for 241 million yuan [5] Group 3 - Luxiao Technology's controlling shareholder plans to reduce its stake by no more than 3% [7] - Fusenmei's vice president and board secretary are under investigation [8] - Zhongchuang Co., Ltd. plans to transfer 2% of its shares through inquiry [10] Group 4 - Anglikang plans to raise 1.16 billion yuan for innovative drug research and industrialization projects [12] - Shenling Environment intends to issue convertible bonds to raise no more than 1 billion yuan [14] - Songcheng Performing Arts plans to acquire 100% equity of Hangzhou Songcheng Industrial for 963 million yuan [16] Group 5 - Demingli plans to raise no more than 3.2 billion yuan for SSD and DRAM expansion projects [17] - Ziyan Food's three shareholders plan to reduce their stake by no more than 276,700 shares [18] - Xinhua Pharmaceutical received a drug registration certificate for a new product [20] Group 6 - Chunqiu Electronics plans to acquire all shares of Danish liquid cooling technology company Asetek A/S for up to 547 million Danish kroner [22] - Tiandi Digital intends to transfer 100% equity of its subsidiary for 49 million yuan [24] - Huaru Technology plans to invest 20 million yuan to establish a fund focusing on new digital technologies [25] Group 7 - *ST Dongtong's stock may be suspended due to regulatory penalties for false reporting [26] - Siryipu is planning to acquire shares of Ningbo Aola Semiconductor and will suspend trading [27] - Purang Co., Ltd. is planning to acquire 49% equity of Noah Changtian and will suspend trading [29] Group 8 - *ST Suwu is facing potential delisting due to significant violations in financial reporting [32]

Core Insights - The demand for flu-related medications, testing, and online consultations has surged dramatically as many regions in China enter the flu season, leading to significant growth in pharmaceutical stocks in the A-share market, particularly in sectors such as pharmaceutical commerce, chemical pharmaceuticals, and innovative drugs [1][5]. Pharmaceutical Sector Performance - The pharmaceutical commercial sector saw an increase of 3.18%, with 28 stocks hitting the daily limit [2]. - Chemical pharmaceuticals rose by 1.97%, with 144 stocks participating in the rally [2]. - Notable stocks in the anti-flu category include Yue Wannianqing and Huaren Health, both reaching the daily limit, while Jindike surged over 14% [2][3]. Sales Data and Trends - Oseltamivir sales in Beijing skyrocketed by 237% over the past week, while another flu medication, Mabalaoshuwei, saw an increase of 180% [4][6]. - Data from Meituan indicates that since November, the demand for flu-specific medications in Beijing has increased by over 130%, with significant growth in sales for both Mabalaoshuwei and Oseltamivir [7][9]. Market Dynamics - The surge in demand for oseltamivir is attributed to its essential role in shortening illness duration and reducing severe cases, making it a necessity for households and medical institutions [9][10]. - Dongyangguang Pharmaceutical, a major supplier of oseltamivir, has established a robust supply chain to ensure stable drug availability during peak flu seasons [11]. Innovation in Flu Medications - The year 2025 is anticipated to be a landmark year for domestic flu medications, with several innovative anti-flu drugs expected to receive approval [12]. - Companies like Siheng Pharmaceutical and Health Yuan are actively submitting NDA applications for new flu treatments, indicating a growing interest in this market segment [13]. Policy and Market Support - The influx of pharmaceutical companies into the anti-flu drug market is driven by the seasonal nature of flu outbreaks and the strategic importance of the biopharmaceutical industry [14]. - National policies are increasingly focused on enhancing public health emergency capabilities, which includes optimizing emergency material reserves and improving procurement mechanisms for flu vaccines and medications [14]. - The ongoing optimization of medical insurance policies is expected to further stimulate demand for innovative anti-flu drugs, providing a solid foundation for flu-related stocks [14].

Core Viewpoint - The innovative drug sector is experiencing significant activity, with multiple companies reaching their daily price limits. Group 1: Company Performance - Zhongheng Group, Fuyuan Pharmaceutical, Hainan Haiyao, and Peking University Pharmaceutical have all hit the daily limit up [1] - Xinhua Pharmaceutical, ST Xiangxue, and Xinnowei are among the stocks with notable gains [1]

Policy Developments - The National Health Commission will hold a press conference on November 27, 2025, to discuss the progress and effectiveness of grassroots medical and health services [1] Industry Initiatives - Beijing's Economic and Information Technology Bureau, along with six departments, has introduced measures to accelerate the promotion of artificial intelligence-assisted diagnostic technologies, including financial support of up to 50 million yuan for selected projects [2] Regulatory Approvals - Saikexide has obtained registration for three medical device products, enhancing its product range in the in vitro diagnostic field [3] - Xinhua Pharmaceutical has received a drug registration certificate for a compound local anesthetic cream, with an estimated sales revenue of 615 million yuan in 2024 [4] - Heng Rui Medicine has received approval for clinical trials of its innovative anti-tumor drug HRS-8364, with a cumulative R&D investment of approximately 21.65 million yuan [5] Capital Market Activities - Suzhou High-tech plans to sell a 47% stake in its medical device subsidiary for 604 million yuan [6] - Shanghai DeYin Technology has completed a Pre-A round financing of several million yuan, backed by listed company Songlin Technology [8] Industry News - Novartis China has responded to rumors of dissolving its county-level team, stating it will adjust its operational model while continuing to serve the county medical market [9] - Samsung Medical's subsidiary has been recommended as a candidate for a procurement project with a total expected amount of approximately 107 million yuan [10] Legal Matters - Foreign companies have filed a Section 337 investigation request against specific antibody-drug conjugates, alleging infringement of trade secrets, involving companies from the US, Netherlands, and China [11] Shareholder Actions - Bid Pharma's shareholder plans to reduce their stake by up to 0.16% between December 17, 2025, and March 16, 2026, due to funding needs [12]

Group 1 - Shandong Xinhua Pharmaceutical (000756) shares increased by over 4%, currently trading at 7.49 HKD with a transaction volume of 95.1843 million HKD [1] - The company received approval from the National Medical Products Administration for the registration of Lidocaine and Prilocaine Cream, which is expected to generate approximately 615 million CNY in sales for public medical institutions in China in 2024 [1] - The current season is seeing a rise in demand for flu medications such as Oseltamivir and Marbofloxacin, with sales of Oseltamivir increasing by 237% and Marbofloxacin by 180% over the past week [1] Group 2 - Xinhua Pharmaceutical is a significant global supplier of antipyretic and analgesic medications, with a product portfolio that includes Ibuprofen, Aspirin, and Meloxicam [1]